share_log

JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $34

Moomoo 24/7 ·  Mar 20 11:46

JP Morgan analyst Anupam Rama maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight and raises the price target from $31 to $34.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment